Predictive Oncology (POAI) 10-Q 13 Aug 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 05, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-36790
Entity Registrant Name	Predictive Oncology Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-1007393
Entity Address, Address Line One	91 43rd Street, Suite 110
Entity Address, City or Town	Pittsburgh
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	15201
City Area Code	412
Local Phone Number	432-1500
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	POAI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		6,666,993
Entity Central Index Key	0001446159
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Assets, Current [Abstract]
Cash	$ 5,331,770	$ 8,728,660
Accounts receivable	387,040	333,697
Inventories	568,215	494,374
Prepaid expense and other assets	597,724	521,700
Total current assets	6,884,749	10,078,431
Property and equipment, net	910,211	1,233,910
Intangibles, net	238,731	252,457
Lease right-of-use assets	2,432,339	2,728,355
Other long-term assets	121,096	124,096
Total assets	10,587,126	14,417,249
Current liabilities:
Accounts payable	1,563,023	1,342,027
Note payable	276,932	150,408
Accrued expenses and other liabilities	1,946,893	1,631,702
Derivative liability	8	1,376
Contract liabilities	269,943	308,091
Lease liability	561,712	517,427
Total current liabilities	4,618,511	3,951,031
Other long-term liabilities	13,661	5,459
Lease liability – net of current portion	1,860,983	2,188,979
Total liabilities	6,493,155	6,145,469
Stockholders’ equity:
Common stock, $.01 par value, 200,000,000 shares authorized, 4,062,853 shares outstanding as of March 31, 2024, and December 31, 2023	57,089	40,629
Additional paid-in capital	179,198,077	175,992,242
Accumulated deficit	(175,161,987)	(167,761,883)
Total stockholders’ equity	4,093,971	8,271,780
Total liabilities and stockholders’ equity	10,587,126	14,417,249
Series B Convertible Preferred Stock [Member]
Stockholders’ equity:
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding as of March 31, 2024, and December 31, 2023	$ 792	$ 792

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Preferred Stock, Shares Authorized (in shares)	20,000,000	20,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01	$ 0.01
Common Stock, Shares Authorized (in shares)	200,000,000	200,000,000
Common Stock, Shares, Outstanding (in shares)	5,708,876	4,062,853
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)	2,300,000	2,300,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, Shares Outstanding (in shares)	79,246	79,246

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 278,722	$ 490,110	$ 698,368	$ 730,005
Cost of sales	152,968	159,761	340,383	279,900
Gross profit	125,754	330,349	357,985	450,105
Operating expenses:
General and administrative expense	2,137,189	2,704,527	4,764,265	5,040,511
Operations expense	893,391	993,042	1,995,584	1,871,560
Sales and marketing expense	284,421	429,103	1,024,155	799,340
Loss on impairment of property and equipment	0	162,905	0	162,905
Total operating expenses	3,315,001	4,289,577	7,784,004	7,874,316
Total operating (loss)	(3,189,247)	(3,959,228)	(7,426,019)	(7,424,211)
Other income	9,461	28,552	28,118	70,780
Other expense	(1,834)	0	(3,571)	0
Gain on derivative instruments	359	7,308	1,368	8,261
Net (loss)	$ (3,181,261)	$ (3,923,368)	$ (7,400,104)	$ (7,345,170)
Net (loss) per common share – basic and diluted (in dollars per share)	$ (0.68)	$ (0.98)	$ (1.7)	$ (1.84)
Weighted average shares used in computation – basic and diluted (in shares)	4,664,771	3,996,512	4,363,812	3,982,384

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Series B Convertible Preferred Stock [Member] Preferred Stock [Member]	Series B Preferred Stock [Member] Preferred Stock [Member]	Series F Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022		79,246	0	3,938,160
Balance at Dec. 31, 2022		$ 792	$ 0	$ 39,382	$ 175,503,634	$ (153,777,916)	$ 21,765,892
Vesting expense		0	0	0	9,287
Net loss		$ 0	$ 0	$ 0	0
Balance (in shares) at Mar. 31, 2023		79,246	79,404	3,969,993
Balance at Mar. 31, 2023		$ 792	$ 794	$ 39,700	175,712,817	(157,199,718)	18,554,385
Shares issued to consultants and others (in shares)		0	0	31,833
Shares issued to consultants and others		$ 0	$ 0	$ 318	200,690	0	201,008
Series F preferred stock dividend		$ 0	$ 794	$ 0		0	0
Preferred Stock Dividends, Shares (in shares)			79,404
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings					(794)
Balance (in shares) at Dec. 31, 2022		79,246	0	3,938,160
Balance at Dec. 31, 2022		$ 792	$ 0	$ 39,382	175,503,634	(153,777,916)	21,765,892
Net loss							(7,345,170)
Balance (in shares) at Jun. 30, 2023		79,246	0	4,006,301
Balance at Jun. 30, 2023		$ 792	$ 0	$ 40,063	175,787,288	(161,123,086)	14,705,057
Balance (in shares) at Mar. 31, 2023		79,246	79,404	3,969,993
Balance at Mar. 31, 2023		$ 792	$ 794	$ 39,700	175,712,817	(157,199,718)	18,554,385
Net loss						(3,923,368)	(3,923,368)
Balance (in shares) at Jun. 30, 2023		79,246	0	4,006,301
Balance at Jun. 30, 2023		$ 792	$ 0	$ 40,063	175,787,288	(161,123,086)	14,705,057
Shares issued to consultants and others (in shares)				10,965
Shares issued to consultants and others				$ 110	68,058		68,168
Vesting expense					5,872		5,872
Shares issued in connection with reverse stock split (in shares)				25,343
Shares issued in connection with reverse stock split				$ 253	(253)
Series F Preferred Stock redemption (in shares)			(79,404)
Series F Preferred Stock redemption			$ (794)		$ 794
Balance (in shares) at Dec. 31, 2023	79,246			4,062,853	175,992,242
Balance at Dec. 31, 2023	$ 792			$ 40,629		(167,761,883)	8,271,780
Vesting expense	0			0			734
Net loss	$ 0			$ 0		(4,218,843)	(4,218,843)
Balance (in shares) at Mar. 31, 2024	79,246			4,062,853	175,992,976
Balance at Mar. 31, 2024	$ 792			$ 40,629		(171,980,726)	4,053,671
Balance (in shares) at Dec. 31, 2023	79,246			4,062,853	175,992,242
Balance at Dec. 31, 2023	$ 792			$ 40,629		(167,761,883)	8,271,780
Net loss							(7,400,104)
Balance (in shares) at Jun. 30, 2024	79,246			5,708,876
Balance at Jun. 30, 2024	$ 792			$ 57,089	$ 179,198,077	(175,161,987)	4,093,971
Balance (in shares) at Mar. 31, 2024	79,246			4,062,853	175,992,976
Balance at Mar. 31, 2024	$ 792			$ 40,629		(171,980,726)	4,053,671
Vesting expense					$ 306		306
Net loss						(3,181,261)	(3,181,261)
Issuance of shares to non-employees (in shares)				38,923
Issuance of shares to non-employees				$ 389	98,864		99,253
Issuance of shares pursuant to At-The-Market financing, net of issuance costs (in shares)				1,607,100
Issuance of shares pursuant to At-The-Market financing, net of issuance costs				$ 16,071	3,105,931		3,122,002
Balance (in shares) at Jun. 30, 2024	79,246			5,708,876
Balance at Jun. 30, 2024	$ 792			$ 57,089	$ 179,198,077	$ (175,161,987)	$ 4,093,971

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flow from operating activities:
Net loss	$ (7,400,104)	$ (7,345,170)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	326,730	417,989
Vesting expense	1,040	15,159
Common stock issued to non-employees	99,253	79,280
(Gain) on derivative instruments	(1,368)	(8,261)
Loss on impairment of property and equipment	0	162,905
Loss on disposal of property and equipment	20,205	903
Inventories
Accounts receivable	(53,343)	(99,653)
Inventories	(73,841)	36,795
Prepaid expense and other assets	(73,024)	47,090
Accounts payable	220,996	66,109
Accrued expenses and other	329,330	(401,002)
Contract liabilities	(38,148)	25,823
Other long-term liabilities	8,202	0
Net cash (used in) operating activities:	(6,634,072)	(7,002,033)
Cash flow from investing activities:
Purchase of property and equipment	(9,510)	(279,727)
Acquisition of intangibles	0	26,018
Net cash (used in) investing activities:	(9,510)	(305,745)
Cash flow from financing activities:
Proceeds from issuance of common stock	3,695,848	0
Costs to issue common stock	(573,846)	0
Proceeds from issuance of financing note payable	275,098	0
Repayment of note payable	(150,408)	0
Net cash provided by financing activities	3,246,692	0
Net (decrease) in cash	(3,396,890)	(7,307,778)
Cash and cash equivalents at beginning of period	8,728,660	22,071,523
Cash and cash equivalents at end of period	5,331,770	14,763,745
Supplemental disclosure for cash flow information:
Cash payments for interest	1,737	0
Non-cash transactions:
Right-of-use assets obtained in exchange for lease liabilities	0	2,997,181
Series F Preferred Stock dividend	0	794
Common stock issued to settle accrued board of directors’ and advisory boards’ compensation	0	189,896
Purchase of property & equipment accrued in accounts payable	0	3,920
Redemption of Series F Preferred Stock	0	794
Reverse Stock Split [Member]
Non-cash transactions:
Common stock issued to settle accrued board of directors’ and advisory boards’ compensation	$ 0	$ 253

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations Predictive Oncology Inc. (“Predictive Oncology” or the “Company”) is a knowledge-driven company focused on applying artificial intelligence (“AI”) to support the development of optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of successful drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials. Predictive Oncology’s mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer. By harnessing the power of machine learning and scientific rigor, the Company believes that it can improve the probability of success of advancing pharmaceutical and biological drug candidates with a higher degree of confidence. The Company operates in three business areas. In its first area, the Company provides optimized, high-confidence drug-response predictions through the application of AI using its proprietary biobank of tumor samples to enable a more informed selection of drug/tumor combinations and increase the probability of success during drug development. The Company also creates and develops tumor-specific 3D cell culture models mimicking the physiological environment of human tissue enabling better-informed decision-making during development. In its second business area, the Company provides services and research using a proprietary self-contained and automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations of biologics. The Company’s third business area produces the United States Food and Drug Administration (“FDA”)-cleared STREAMWAY® System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The Company has three Note 12 Segments ● Pittsburgh segment: ● Birmingham segment ● Eagan segment Going Concern These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, substantial doubt about the Company’s ability to continue as a going concern exists. The Company has incurred significant and recurring losses from operations for the past several years and, as of June 30, 2024, had an accumulated deficit of $175,161,987. The Company had cash and cash equivalents of $5,331,770 as of June 30, 2024, and needs to raise significant additional capital to meet its operating needs. The Company had short-term obligations of $4,618,511 and long-term operating lease obligations of $1,860,983 as of June 30, 2024. The Company does not expect to generate sufficient operating revenue to sustain its operations in the near term. During the six months ended June 30, 2024, the Company incurred negative cash flows from operations of $6,634,072. Although the Company has attempted to improve its cash flows from operations by bolstering revenues and continues to seek ways to generate revenue through business development activities, there is no guarantee that the Company will be able to improve its cash flows from operations sufficiently or achieve profitability in the near term. As a result of these conditions, substantial doubt exists about the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. The Company is evaluating alternatives to obtain the required additional funding to maintain future operations. These alternatives may include, but are not limited to, equity financing, issuing debt, entering into other financing arrangements, or monetizing operating businesses or assets. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing stockholders or that result in the Company’s existing stockholders losing part or all of their investment. Despite these potential sources of funding, the Company may be unable to access financing or obtain additional liquidity when needed or under acceptable terms, if at all. If such financing or adequate funds from operations are not available, the Company would be forced to limit its business activities and the Company could default on existing payment obligations, which would have a material adverse effect on its financial condition and results of operations, and the Company may ultimately be required to cease its operations and liquidate its business. The Company’s condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. Basis of Presentation The Company has prepared the condensed consolidated financial statements and related unaudited financial information in the notes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim condensed consolidated financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations, and its cash flows for the interim periods. These interim condensed consolidated financial statements reflect all intercompany eliminations. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto contained in the Annual Report on Form 10-K filed with the SEC on March 28, 2024. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates. Estimates are used in the following areas, among others: variable consideration associated with revenue recognition, stock-based compensation expense, fair value of long-lived assets for impairment analyses, the valuation allowance included in the deferred income tax calculation, accrued expenses, and fair value of derivative liabilities. Note 1 to the annual consolidated financial statements contained in the Annual Report on Form 10-K filed with the SEC on March 28, 2024, describes the significant accounting policies and estimates used in preparation of the consolidated financial statements. There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2024. Principles of Consolidation The Company had two wholly owned subsidiaries, Helomics Corporation and Skyline Medical, Inc. (“Skyline Medical”), as of June 30, 2024, and December 31, 2023, and for the three and six months ended June 30, 2024, and 2023. The condensed consolidated financial statements include the accounts of the Company and these wholly owned subsidiaries after elimination of intercompany transactions and balances as of June 30, 2024, and December 31, 2023, and for the three and six months ended June 30, 2024, and 2023. Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalent balances with high quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. As of June 30, 2024, accounts receivable from a single customer represented 11% of the Company’s total accounts receivable. As of December 31, 2023, accounts receivable from a single customer represented 16% of the Company’s total accounts receivable. Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not listed below either were assessed and determined to be not applicable or are currently expected to have no impact on the condensed consolidated financial statements of the Company. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Note 2 - Collaborative Arrangem

Note 2 - Collaborative Arrangements and Contracts With Customers	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	NOTE 2 COLLABORATIVE ARRANGEMENTS AND CONTRACTS WITH CUSTOMERS Collaboration Agreement with Cancer Research Horizons On March 16, 2023, the Company entered into a Collaboration Agreement (the “CRH Agreement”) with Cancer Research Horizons (“CRH”), pursuant to which the Company used its PEDAL technology to evaluate CRH pre-clinical drug inhibitors of Glutaminase to determine which cancer types and patient populations were most likely to respond to treatment with those compounds (the “Project”). Under the CRH Agreement, both parties retained rights to their respective background intellectual property. Rights to reports, findings, supporting data, and materials (“Project Intellectual Property”) that were generated by the Company pursuant to its performance under the CRH Agreement vested exclusively in CRH. Each party funded its own participation in the Project. Costs incurred to participate in the CRH Agreement were recorded in Cost of sales in the Company’s Consolidated Statement of Net Loss for the year ended December 31, 2023. Pursuant to the CRH Agreement, the Company shall receive a percentage of net revenue, as defined in the agreement, received by CRH for the commercialization of the CRH Candidates and any CRH Derivatives (each as defined in the CRH Agreement). The percentage of net revenue varies depending on the stage of development. The revenue sharing fees represent variable consideration, which is measured using the expected value method under ASC 606 based on the actual net revenues earned by CRH under Relevant Transfer Agreements (as defined in the CRH Agreement) relating to the CRH Candidates and CRH Derivatives. Due to the uncertainty associated with the timing and amount of revenue sharing fees, the Company concluded that the revenue sharing fees should be fully constrained until such time that Relevant Transfer Agreements have been entered and net revenues have been earned. These estimates will be reassessed at each reporting period. During the six months ended June 30, 2024, and 2023, the Company recognized no Contracts with Customers and Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of June 30, 2024, and December 31, 2023, accounts receivable totaled $387,040 and $333,697, respectively. The allowance for accounts receivable balance was $0 as of both June 30, 2024, and December 31, 2023. During the three months ended June 30, 2024, revenues from three customers were 11%, 11%, and 12% of the Company’s total revenue, respectively. During the six months ended June 30, 2024, revenues from a single customer were 34% of the Company’s total revenue. During the three months ended June 30, 2023, revenues from three three Advance payments received in excess of revenues recognized are classified as contract liabilities until such time as the revenue recognition criteria have been met. The Company’s contract liabilities, related primarily to development of 3D models and STREAMWAY maintenance plans, were $283,604 and $313,550 as of June 30, 2024, and December 31, 2023, respectively. During the three and six months ended June 30, 2024, the Company recognized revenue of $49,165 and $66,139, respectively, related primarily to deposits for development of 3D models and STREAMWAY maintenance plans that were included in contract liabilities as of December 31, 2023. The Company’s contract liabilities as of June 30, 2024, primarily represent its remaining performance obligations. The Company’s long-term contract liabilities are reported in Other long-term liabilities in the condensed consolidated balance sheets.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3 FAIR VALUE MEASUREMENTS The following table summarizes the Company’s fair value hierarchy for its assets and liabilities measured at fair value on a recurring basis: June 30, 2024 Fair Value Level 1 Level 2 Level 3 Assets: Money market funds $ 4,000,000 $ 4,000,000 $ - $ - Liabilities: Derivatives $ 8 $ - $ - $ 8 December 31, 2023 Fair Value Level 1 Level 2 Level 3 Liabilities: Derivatives $ 1,376 $ - $ - $ 1,376

Note 4 - Inventories

Note 4 - Inventories	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 4 INVENTORIES Inventory balances were as follows: As of June 30, 2024 As of December 31, 2023 Raw materials $ 313,847 $ 239,998 Work-in-process - - Finished goods 254,368 254,376 Total $ 568,215 $ 494,374

Note 5 - Property and Equipment

Note 5 - Property and Equipment	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 5 PROPERTY AND EQUIPMENT The Company’s property and equipment, net consisted of the following: As of June 30, 2024 As of December 31, 2023 Computers, software, and office equipment $ 481,314 $ 480,882 Leasehold improvements 506,162 506,162 Laboratory equipment 3,605,304 3,670,097 Warehouse and manufacturing equipment 139,763 133,285 Demo equipment 31,554 31,554 Total 4,764,097 4,821,980 Less: Accumulated depreciation (3,853,886 ) (3,588,070 ) Total Property and equipment, net $ 910,211 $ 1,233,910 Depreciation expense, recorded within general and administrative expenses, was $157,302 and $173,100 for the three months ended June 30, 2024, and 2023, respectively, and $313,004 and $404,289 during the six months ended June 30, 2024, and 2023, respectively. No

Note 6 - Intangible Assets

Note 6 - Intangible Assets	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 6 INTANGIBLE ASSETS The Company’s intangibles, net consisted of the following: As of June 30, 2024 As of December 31, 2023 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Net Carrying Amount Patents & Trademarks $ 535,096 $ (296,365 ) $ 238,731 $ 535,096 $ (282,639 ) $ 252,457 Finite-lived intangible assets are amortized over their estimated useful lives. Amortization expense, recorded within general and administrative expenses, was $6,863 and $7,035 during the three months ended June 30, 2024, and 2023, respectively, and $13,726 and $13,700 during the six months ended June 30, 2024, and 2023, respectively. Accumulated amortization is included in Intangibles, net in the condensed consolidated balance sheets. The following table outlines the estimated future amortization expense related to intangible assets held as of June 30, 2024: Year Ending December 31, Expense Remainder of 2024 $ 13,726 2025 27,451 2026 27,451 2027 27,451 2028 27,451 Thereafter 115,201 Total $ 238,731 The Company reviews finite-lived intangible assets for impairment in accordance with ASC 360, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates. No

Note 7 - Leases

Note 7 - Leases	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 7 LEASES The Company’s corporate offices and other offices are located in Pittsburgh, Pennsylvania. The leases are effective through February 29, 2028. The Company has an office in Birmingham, Alabama, which is used for office space, warehousing, and laboratory operations. The lease is effective through August 31, 2025. The Company has an office in Eagan, Minnesota, which is used for office space and manufacturing. This lease is effective through May 31, 2025. Lease expense under operating lease arrangements, recorded within general and administrative expenses, was $227,762 and $220,847 for the three months ended June 30, 2024, and 2023, respectively, and $455,403 and $434,862 for the six months ended June 30, 2024, and 2023, respectively. The following table summarizes other information related to the Company’s operating leases: June 30, 2024 June 30, 2023 Weighted average remaining lease term – operating leases in years 3.53 4.46 Weighted average discount rate – operating leases 12 % 12 % The Company’s operating lease obligations as of June 30, 2024, which include expected lease extensions that are reasonably certain of renewal, were as follows: Remainder of 2024 $ 375,487 2025 857,622 2026 803,724 2027 827,909 2028 139,022 Total lease payments 3,003,764 Less: interest (581,069 ) Present value of lease liabilities $ 2,422,695

Note 8 - Note Payable

Note 8 - Note Payable	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 8 NOTE PAYABLE In June 2023, the Company purchased director and officer insurance policies with a policy period ending June 2024. In July 2023, the Company financed $364,721 of its total premium by entering into a note payable with a finance provider that required ten no In June 2024, the Company purchased director and officer insurance policies with a policy period ending June 2025 and financed $275,098 of its total premium by entering into a note payable with a finance provider that required ten

Note 9 - Derivatives

Note 9 - Derivatives	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 9 DERIVATIVES Certain warrants issued to placement agents were determined to be a derivative liability due to certain features of the warrants which could, in certain circumstances, result in the holder receiving the fair value of the outstanding warrants in the same type of consideration as the common stockholders. As a result, in those circumstances, the amount of consideration would differ from that provided to holders of common stock, therefore, the warrants were classified as a liability. The fair value of the placement agent warrants issued in connection with the March 2020 private placement was determined to be $0 and $135 as of June 30, 2024, and December 31, 2023, respectively. The Company recorded gains on the change in fair value of the placement agent warrants of $13 and $1,900 during the three months ended June 30, 2024, and 2023, respectively, and $135 and $2,319 during the six months ended June 30, 2024, and 2023, respectively. The placement agent warrants expire in March 2025. The fair value of the placement agent warrants issued in connection with the May 2020 offering of securities was determined to be $0 and $333 as of June 30, 2024, and December 31, 2023, respectively. The Company recorded gains on the change in fair value of the placement agent warrants of $57 and $2,435 during the three months ended June 30, 2024, and 2023, respectively, and $333 and $2,770 during the six months ended June 30, 2024, and 2023, respectively. The placement agent warrants expire in May 2025. The placement agent warrants issued in connection with the June 2020 warrant exercise and issuance had a fair value of $8 and $908 as of June 30, 2024, and December 31, 2023, respectively. The Company recorded gains on the change in fair value of the placement agent warrants of $289 and $2,973 during the three months ended June 30, 2024, and 2023, respectively, and $900 and $3,172 during the six months ended June 30, 2024, and 2023, respectively. The placement agent warrants expire in June 2025. The table below discloses changes in value of the Company’s embedded derivative liabilities discussed above. Derivative liability balance as of December 31, 2022 $ 13,833 (Gain) recognized to revalue derivative instrument at fair value (953 ) Derivative liability balance as of March 31, 2023 $ 12,880 (Gain) recognized to revalue derivative instrument at fair value (7,308 ) Derivative liability balance as of June 30, 2023 $ 5,572 Derivative liability balance as of December 31, 2023 $ 1,376 (Gain) recognized to revalue derivative instrument at fair value (1,009 ) Derivative liability balance as of March 31, 2024 $ 367 (Gain) recognized to revalue derivative instrument at fair value (359 ) Derivative liability balance as of June 30, 2024 $ 8

Note 10 - Stockholders' Equity,

Note 10 - Stockholders' Equity, Stock Options and Warrants	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Equity [Text Block]	NOTE 10 STOCKHOLDERS EQUITY, STOCK OPTIONS AND WARRANTS Series F Preferred Stock Dividend and Reverse Stock Split On March 16, 2023, the Board of Directors of the Company authorized the issuance of 80,000 shares of Series F Preferred Stock, par value $0.01 per share. On March 16, 2023, the Board of Directors of the Company declared a dividend of one On April 19, 2023, the Company completed a one-for- twenty Redemption of Series F Preferred Stock On April 17, 2023, the Company convened a special meeting of stockholders, which was adjourned due to the lack of a quorum and reconvened on April 19, 2023 (the “Special Meeting”), at which the Company’s stockholders approved a proposal to amend the Company’s certificate of incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-25, with such ratio to be determined by the Company’s Board of Directors (the “Reverse Split Proposal”). All shares of Series F Preferred Stock that were not present in person or by proxy at the Special Meeting as of immediately prior to the opening of the polls (the “Initial Redemption Time”) were automatically redeemed (the “Initial Redemption”). All outstanding shares of Series F Preferred Stock that were not redeemed pursuant to the Initial Redemption were redeemed automatically upon the approval by the Company’s stockholders of the Reverse Split Proposal (the “Subsequent Redemption” and, together with the Initial Redemption, the “Redemption”). Both the Initial Redemption and the Subsequent Redemption occurred on April 19, 2023. As a result, no At The Market Offering On May 3, 2024, the Company entered into an ATM Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), to sell shares of the Company’s common stock, par value $0.01 per share (the “Shares”), having an aggregate sales price of up to $3,696,000, from time to time, through an “at the market offering” program pursuant to which Wainwright will act as sales agent. Subject to the terms and conditions of the Sales Agreement, Wainwright is permitted to sell the Shares by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The Sales Agreement provides that Wainwright will be entitled to compensation for its services of 3.0% of the gross sales price of all shares sold through Wainwright under the Sales Agreement. As of June 30, 2024, the Company has sold 1,607,100 shares of common stock at an average price of approximately $2.30 per share, resulting in aggregate gross proceeds of approximately $3,696,000. Equity Incentive Plan The Company’s Amended and Restated 2012 Stock Incentive Plan (the “2012 Plan”) allows for the issuance of incentive and non-qualified stock options, stock appreciation rights, stock awards, restricted stock, restricted stock units (“RSUs”) and performance awards to employees, directors, and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the market price on the date of issuance. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options outstanding under this plan have a contractual life of ten years. ASC 718, Compensation Stock Compensation Valuation and Accounting for Stock Options and Warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term. During the three and six months ended June 30, 2024, there were no options or warrants granted. The fair value of each stock option grant was estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: Six Months Ended June 30, 2024 2023 Stock Options Expected dividend yield - 0.0% Expected stock price volatility - 90.8% –91.6% Risk-free interest rate - 3.38% –3.72% Expected life (in years) - 10 Stock Options and Warrants Granted by the Company The following summarizes transactions for stock options and warrants for the period indicated: Stock Options Warrants Number of Average Number of Average Outstanding as of December 31, 2023 47,664 $ 82.23 1,806,589 $ 21.52 Issued - - - - Forfeited (233 ) 4.67 - - Expired (1,019 ) 105.99 (77,285 ) 33.86 Outstanding as of June 30, 2024 46,412 $ 82.09 1,729,304 $ 20.97 Stock-based compensation expense, net of forfeitures, recognized for the three months ended June 30, 2024, and 2023, was $307 and $5,872, respectively. Stock-based compensation expense, net of forfeitures, recognized for the six months ended June 30, 2024, and 2023, was $1,040 and $15,159, respectively. Stock-based compensation expense is recorded within each of the captions comprising Operating expenses. The Company has $182 of unrecognized compensation expense related to unvested stock options that is expected to be recognized over the next 10 months.

Note 11 - Loss Per Share

Note 11 - Loss Per Share	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 11 LOSS PER SHARE The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Numerator: Net (loss) attributable to common stockholders: basic and diluted calculation $ (3,181,261 ) $ (3,923,368 ) $ (7,400,104 ) $ (7,345,170 ) Denominator: Weighted average common shares outstanding - basic 4,664,771 3,996,512 4,363,812 3,982,384 Effect of diluted stock options, warrants, and preferred stock (1) - - - - Weighted average common shares outstanding - diluted 4,664,771 3,996,512 4,363,812 3,982,384 (Loss) per common share - basic and diluted $ (0.68 ) $ (0.98 ) $ (1.70 ) $ (1.84 ) (1) The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Three and Six Months Ended June 30, 2024 2023 Options 46,412 48,037 RSUs - 2,500 Warrants 1,729,304 1,812,379 Preferred stock: Series B 16 16

Note 12 - Segments

Note 12 - Segments	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 12 SEGMENTS The Company has determined its operating segments in accordance with ASC 280 – Segment Reporting. Factors used to determine the Company’s reportable segments include the availability of separate financial statements, the existence of locally based leadership across geographic regions, the economic factors affecting each segment, and the evaluation of operating results at the segment level. The Chief Operating Decision Maker (“CODM”) allocates the Company’s resources for each of the operating segments and evaluates their relative performance. Each operating segment listed below has separate financial statements and locally based leadership that are evaluated based on the results of their respective segments. It should be noted that the operating segments below have different products and services. The financial information is consolidated and evaluated regularly by the CODM in assessing performance and allocating resources. The Company has three ● Pittsburgh segment: ● Birmingham segment ● Eagan segment All revenues are earned from external customers. The tables below summarize the Company’s segment reporting as of June 30, 2024, and December 31, 2023, and for the three and six months ended June 30, 2024, and 2023. Three Months Ended June 30, 2024 Pittsburgh Birmingham Eagan Corporate Total Revenue $ 67,255 $ 20,813 $ 190,654 $ - $ 278,722 Depreciation and amortization (31,408 ) (123,714 ) (7,224 ) (1,819 ) (164,165 ) Segment loss $ (1,010,978 ) $ (459,012 ) $ (265,580 ) $ (1,445,691 ) $ (3,181,261 ) Six Months Ended June 30, 2024 Pittsburgh Birmingham Eagan Corporate Total Revenue $ 72,113 $ 31,822 $ 594,433 $ - $ 698,368 Depreciation and amortization (63,505 ) (244,508 ) (15,047 ) (3,670 ) (326,730 ) Segment loss $ (2,207,043 ) $ (924,174 ) $ (455,156 ) $ (3,813,731 ) $ (7,400,104 ) June 30, 2024 Pittsburgh Birmingham Eagan Corporate Total Assets $ 2,968,289 $ 696,017 $ 1,140,234 $ 5,782,586 $ 10,587,126 Three Months Ended June 30, 2023 Pittsburgh Birmingham Eagan Corporate Total Revenue $ 13,844 $ 84,880 $ 391,386 $ - $ 490,110 Depreciation and amortization (31,945 ) (136,194 ) (9,973 ) (2,023 ) (180,135 ) Segment loss $ (1,594,587 ) $ (585,443 ) $ (281,687 ) $ (1,461,651 ) $ (3,923,368 ) Six Months Ended June 30, 2023 Pittsburgh Birmingham Eagan Corporate Total Revenue $ 24,471 $ 98,529 $ 607,005 $ - $ 730,005 Depreciation and amortization (143,767 ) (253,794 ) (16,751 ) (3,677 ) (417,989 ) Segment loss $ (2,753,692 ) $ (1,068,139 ) $ (567,084 ) $ (2,956,255 ) $ (7,345,170 ) December 31, 2023 Pittsburgh Birmingham Eagan Corporate Total Assets $ 3,263,270 $ 981,914 $ 1,390,031 $ 8,782,034 $ 14,417,249

Note 13 - Subsequent Events

Note 13 - Subsequent Events	6 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 13 SUBSEQUENT EVENTS Warrant Inducement Transaction On July 25, 2024, the Company entered into definitive agreements with certain of its existing warrant holders for the exercise of warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The gross proceeds to the Company from the exercise of the existing warrants were approximately $1.26 million, prior to deducting placement agent fees and transaction expenses payable by the Company. In consideration for the immediate cash exercise of the warrants, the Company concurrently issued to the warrant holders new unregistered Series A warrants to purchase up to 958,117 shares of common stock (the “Series A Warrants”) and new Series B warrants to purchase up to 958,117 shares of common stock (the “Series B Warrants”). The Series A Warrants and the Series B Warrants have an exercise price of $1.07 per share and are exercisable immediately upon issuance. The Series A Warrants have a term equal to five The transactions described above closed on July 26, 2024. Wainwright acted as the exclusive placement agent for the above-mentioned transactions. The Company paid Wainwright as consideration (i) an aggregate cash fee equal to 7.0% of the gross proceeds from the exercise of the existing warrants, (ii) a management fee equal to 1.0% of the aggregate gross proceeds from the exercise of the existing warrants, (iii) $35,000 for expenses, and (iv) $15,950 for clearing fees. Additionally, the Company issued to Wainwright (or its designees) as compensation, warrants to purchase up to 67,068 shares of common stock of the Company (equal to 7.0% of the aggregate number of existing warrants exercised in the offering) (the “Placement Agent Warrants”). The Placement Agent Warrants have a term of five Strategic Cost Savings Initiative On July 25, 2024, the Company’s Board of Directors approved a plan to implement a strategic cost savings initiative, primarily related to the consolidation of the operations of the Company’s Birmingham laboratory into its Pittsburgh laboratory. The Company began implementing the cost savings initiative in August 2024 and continues to review its progress and effectiveness, including the impact of the changes on the Company’s operating segments and the full financial effect on our consolidated financial statements.

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Jun. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	Not
Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Nature Of Operations and Going Concern Policy [Policy Text Block]	Going Concern These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, substantial doubt about the Company’s ability to continue as a going concern exists. The Company has incurred significant and recurring losses from operations for the past several years and, as of June 30, 2024, had an accumulated deficit of $175,161,987. The Company had cash and cash equivalents of $5,331,770 as of June 30, 2024, and needs to raise significant additional capital to meet its operating needs. The Company had short-term obligations of $4,618,511 and long-term operating lease obligations of $1,860,983 as of June 30, 2024. The Company does not expect to generate sufficient operating revenue to sustain its operations in the near term. During the six months ended June 30, 2024, the Company incurred negative cash flows from operations of $6,634,072. Although the Company has attempted to improve its cash flows from operations by bolstering revenues and continues to seek ways to generate revenue through business development activities, there is no guarantee that the Company will be able to improve its cash flows from operations sufficiently or achieve profitability in the near term. As a result of these conditions, substantial doubt exists about the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. The Company is evaluating alternatives to obtain the required additional funding to maintain future operations. These alternatives may include, but are not limited to, equity financing, issuing debt, entering into other financing arrangements, or monetizing operating businesses or assets. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing stockholders or that result in the Company’s existing stockholders losing part or all of their investment. Despite these potential sources of funding, the Company may be unable to access financing or obtain additional liquidity when needed or under acceptable terms, if at all. If such financing or adequate funds from operations are not available, the Company would be forced to limit its business activities and the Company could default on existing payment obligations, which would have a material adverse effect on its financial condition and results of operations, and the Company may ultimately be required to cease its operations and liquidate its business. The Company’s condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The Company has prepared the condensed consolidated financial statements and related unaudited financial information in the notes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim condensed consolidated financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations, and its cash flows for the interim periods. These interim condensed consolidated financial statements reflect all intercompany eliminations. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto contained in the Annual Report on Form 10-K filed with the SEC on March 28, 2024. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates. Estimates are used in the following areas, among others: variable consideration associated with revenue recognition, stock-based compensation expense, fair value of long-lived assets for impairment analyses, the valuation allowance included in the deferred income tax calculation, accrued expenses, and fair value of derivative liabilities. Note 1 to the annual consolidated financial statements contained in the Annual Report on Form 10-K filed with the SEC on March 28, 2024, describes the significant accounting policies and estimates used in preparation of the consolidated financial statements. There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2024.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The Company had two wholly owned subsidiaries, Helomics Corporation and Skyline Medical, Inc. (“Skyline Medical”), as of June 30, 2024, and December 31, 2023, and for the three and six months ended June 30, 2024, and 2023. The condensed consolidated financial statements include the accounts of the Company and these wholly owned subsidiaries after elimination of intercompany transactions and balances as of June 30, 2024, and December 31, 2023, and for the three and six months ended June 30, 2024, and 2023.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalent balances with high quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. As of June 30, 2024, accounts receivable from a single customer represented 11% of the Company’s total accounts receivable. As of December 31, 2023, accounts receivable from a single customer represented 16% of the Company’s total accounts receivable.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not listed below either were assessed and determined to be not applicable or are currently expected to have no impact on the condensed consolidated financial statements of the Company. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	June 30, 2024 Fair Value Level 1 Level 2 Level 3 Assets: Money market funds $ 4,000,000 $ 4,000,000 $ - $ - Liabilities: Derivatives $ 8 $ - $ - $ 8 December 31, 2023 Fair Value Level 1 Level 2 Level 3 Liabilities: Derivatives $ 1,376 $ - $ - $ 1,376

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of June 30, 2024 As of December 31, 2023 Raw materials $ 313,847 $ 239,998 Work-in-process - - Finished goods 254,368 254,376 Total $ 568,215 $ 494,374

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of June 30, 2024 As of December 31, 2023 Computers, software, and office equipment $ 481,314 $ 480,882 Leasehold improvements 506,162 506,162 Laboratory equipment 3,605,304 3,670,097 Warehouse and manufacturing equipment 139,763 133,285 Demo equipment 31,554 31,554 Total 4,764,097 4,821,980 Less: Accumulated depreciation (3,853,886 ) (3,588,070 ) Total Property and equipment, net $ 910,211 $ 1,233,910

Note 6 - Intangible Assets (Tab

Note 6 - Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of June 30, 2024 As of December 31, 2023 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Net Carrying Amount Patents & Trademarks $ 535,096 $ (296,365 ) $ 238,731 $ 535,096 $ (282,639 ) $ 252,457
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ending December 31, Expense Remainder of 2024 $ 13,726 2025 27,451 2026 27,451 2027 27,451 2028 27,451 Thereafter 115,201 Total $ 238,731

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Lease, Cost [Table Text Block]	June 30, 2024 June 30, 2023 Weighted average remaining lease term – operating leases in years 3.53 4.46 Weighted average discount rate – operating leases 12 % 12 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Remainder of 2024 $ 375,487 2025 857,622 2026 803,724 2027 827,909 2028 139,022 Total lease payments 3,003,764 Less: interest (581,069 ) Present value of lease liabilities $ 2,422,695

Note 9 - Derivatives (Tables)

Note 9 - Derivatives (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative liability balance as of December 31, 2022 $ 13,833 (Gain) recognized to revalue derivative instrument at fair value (953 ) Derivative liability balance as of March 31, 2023 $ 12,880 (Gain) recognized to revalue derivative instrument at fair value (7,308 ) Derivative liability balance as of June 30, 2023 $ 5,572 Derivative liability balance as of December 31, 2023 $ 1,376 (Gain) recognized to revalue derivative instrument at fair value (1,009 ) Derivative liability balance as of March 31, 2024 $ 367 (Gain) recognized to revalue derivative instrument at fair value (359 ) Derivative liability balance as of June 30, 2024 $ 8

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity, Stock Options and Warrants (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Six Months Ended June 30, 2024 2023 Stock Options Expected dividend yield - 0.0% Expected stock price volatility - 90.8% –91.6% Risk-free interest rate - 3.38% –3.72% Expected life (in years) - 10
Share-Based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding as of December 31, 2023 47,664 $ 82.23 1,806,589 $ 21.52 Issued - - - - Forfeited (233 ) 4.67 - - Expired (1,019 ) 105.99 (77,285 ) 33.86 Outstanding as of June 30, 2024 46,412 $ 82.09 1,729,304 $ 20.97

Note 11 - Loss Per Share (Table

Note 11 - Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Numerator: Net (loss) attributable to common stockholders: basic and diluted calculation $ (3,181,261 ) $ (3,923,368 ) $ (7,400,104 ) $ (7,345,170 ) Denominator: Weighted average common shares outstanding - basic 4,664,771 3,996,512 4,363,812 3,982,384 Effect of diluted stock options, warrants, and preferred stock (1) - - - - Weighted average common shares outstanding - diluted 4,664,771 3,996,512 4,363,812 3,982,384 (Loss) per common share - basic and diluted $ (0.68 ) $ (0.98 ) $ (1.70 ) $ (1.84 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three and Six Months Ended June 30, 2024 2023 Options 46,412 48,037 RSUs - 2,500 Warrants 1,729,304 1,812,379 Preferred stock: Series B 16 16

Note 12 - Segments (Tables)

Note 12 - Segments (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended June 30, 2024 Pittsburgh Birmingham Eagan Corporate Total Revenue $ 67,255 $ 20,813 $ 190,654 $ - $ 278,722 Depreciation and amortization (31,408 ) (123,714 ) (7,224 ) (1,819 ) (164,165 ) Segment loss $ (1,010,978 ) $ (459,012 ) $ (265,580 ) $ (1,445,691 ) $ (3,181,261 ) Six Months Ended June 30, 2024 Pittsburgh Birmingham Eagan Corporate Total Revenue $ 72,113 $ 31,822 $ 594,433 $ - $ 698,368 Depreciation and amortization (63,505 ) (244,508 ) (15,047 ) (3,670 ) (326,730 ) Segment loss $ (2,207,043 ) $ (924,174 ) $ (455,156 ) $ (3,813,731 ) $ (7,400,104 ) June 30, 2024 Pittsburgh Birmingham Eagan Corporate Total Assets $ 2,968,289 $ 696,017 $ 1,140,234 $ 5,782,586 $ 10,587,126 Three Months Ended June 30, 2023 Pittsburgh Birmingham Eagan Corporate Total Revenue $ 13,844 $ 84,880 $ 391,386 $ - $ 490,110 Depreciation and amortization (31,945 ) (136,194 ) (9,973 ) (2,023 ) (180,135 ) Segment loss $ (1,594,587 ) $ (585,443 ) $ (281,687 ) $ (1,461,651 ) $ (3,923,368 ) Six Months Ended June 30, 2023 Pittsburgh Birmingham Eagan Corporate Total Revenue $ 24,471 $ 98,529 $ 607,005 $ - $ 730,005 Depreciation and amortization (143,767 ) (253,794 ) (16,751 ) (3,677 ) (417,989 ) Segment loss $ (2,753,692 ) $ (1,068,139 ) $ (567,084 ) $ (2,956,255 ) $ (7,345,170 ) December 31, 2023 Pittsburgh Birmingham Eagan Corporate Total Assets $ 3,263,270 $ 981,914 $ 1,390,031 $ 8,782,034 $ 14,417,249

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual)	6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Number of Tumor Samples	150,000
Number of Operating Segments	3
Retained Earnings (Accumulated Deficit)	$ 175,161,987		$ 167,761,883
Cash and Cash Equivalents, at Carrying Value	5,331,770		8,728,660
Liabilities, Current	4,618,511		3,951,031
Operating Lease, Liability, Noncurrent	1,860,983		$ 2,188,979
Net Cash Provided by (Used in) Operating Activities	$ 6,634,072	$ 7,002,033

Note 2 - Collaborative Arrang_2

Note 2 - Collaborative Arrangements and Contracts With Customers (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Accounts Receivable, after Allowance for Credit Loss, Current	$ 387,040		$ 387,040		$ 333,697
Accounts Receivable, Allowance for Credit Loss, Current	0		0		0
Contract with Customer, Liability	283,604		283,604		$ 313,550
Contract with Customer, Liability, Revenue Recognized	$ 49,165		$ 66,139
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Number of Customers		3		3
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration Risk, Percentage	11%	11%		10%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration Risk, Percentage	11%	15%		12%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Three [Member]
Concentration Risk, Percentage	12%	24%		16%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Single Customer [Member]
Concentration Risk, Percentage			34%
Cancer Research Horizons [Member] | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer			$ 0	$ 0

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements - Fair Value of Assets and Liabilities on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Derivatives	$ 8	$ 1,376
Money Market Funds [Member]
Money market funds	4,000,000
Fair Value, Inputs, Level 1 [Member]
Derivatives	0	0
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Money market funds	4,000,000
Fair Value, Inputs, Level 2 [Member]
Derivatives	0	0
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Money market funds	0
Fair Value, Inputs, Level 3 [Member]
Derivatives	8	$ 1,376
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Money market funds	$ 0

Note 4 - Inventories - Schedule

Note 4 - Inventories - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Raw materials	$ 313,847	$ 239,998
Work-In-Process	0	0
Finished goods	254,368	254,376
Total	$ 568,215	$ 494,374

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Depreciation, Total	$ 157,302	$ 173,100	$ 313,004	$ 404,289
Property, Plant and Equipment [Member]
Asset Impairment Charges		$ 162,905	$ 0

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Property, Plant, and Equipment Gross	$ 4,764,097	$ 4,821,980
Less: Accumulated depreciation	(3,853,886)	(3,588,070)
Total Property and Equipment, Net	910,211	1,233,910
Office Equipment [Member]
Property, Plant, and Equipment Gross	481,314	480,882
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	506,162	506,162
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	3,605,304	3,670,097
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	139,763	133,285
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 31,554	$ 31,554

Note 6 - Intangible Assets (Det

Note 6 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Amortization of Intangible Assets	$ 6,863	$ 7,035	$ 13,726	$ 13,700
Impairment of Intangible Assets (Excluding Goodwill)			$ 0

Note 6 - Intangible Assets - Co

Note 6 - Intangible Assets - Components of Intangible Assets (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Net Carrying Amount	$ 238,731
Patents and Trademarks [Member]
Gross Carrying Costs	535,096	$ 535,096
Accumulated Amortization	(296,365)	(282,639)
Net Carrying Amount	$ 238,731	$ 252,457

Note 6 - Intangible Assets - Es

Note 6 - Intangible Assets - Estimated Future Amortization Expense (Details)	Jun. 30, 2024 USD ($)
Remainder of 2024	$ 13,726
2025	27,451
2026	27,451
2027	27,451
2028	27,451
Thereafter	115,201
Total	$ 238,731

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating Lease, Expense	$ 227,762	$ 220,847	$ 455,403	$ 434,862

Note 7 - Leases - Lease Informa

Note 7 - Leases - Lease Information (Details)	Jun. 30, 2024	Jun. 30, 2023
Weighted average remaining lease term – operating leases in years (Year)	3 years 6 months 10 days	4 years 5 months 15 days
Weighted average discount rate – operating leases	12%	12%

Note 7 - Leases - Rent Obligati

Note 7 - Leases - Rent Obligation (Details)	Jun. 30, 2024 USD ($)
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year	$ 375,487
2025	857,622
2026	803,724
2027	827,909
2028	139,022
Total lease payments	3,003,764
Less: interest	(581,069)
Present value of lease liabilities	$ 2,422,695

Note 8 - Note Payable (Details

Note 8 - Note Payable (Details Textual)	1 Months Ended
	Jun. 30, 2024 USD ($)	Jul. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)
Insurance Policy Financing [Member]
Debt Instrument, Face Amount		$ 364,721
Debt Instrument, Number of Monthly Installment		10
Debt Instrument, Interest Rate, Stated Percentage		9.25%
Notes Payable	$ 0		$ 150,408
Insurance Policy Financing June 2024 [Member]
Debt Instrument, Face Amount	$ 275,098
Debt Instrument, Number of Monthly Installment	10
Debt Instrument, Interest Rate, Stated Percentage	8%
Notes Payable	$ 276,932

Note 9 - Derivatives (Details T

Note 9 - Derivatives (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Agent Warrants In Connection With March 2020 Private Placement [Member]
Derivative Liability, Total	$ 0		$ 0		$ 135
Derivative, Gain (Loss) on Derivative, Net, Total	13	$ 1,900	135	$ 2,319
Agent Warrants Issued in Connection with May 2020 Offering [Member]
Derivative Liability, Total	0		0		333
Derivative, Gain (Loss) on Derivative, Net, Total	57	2,435	333	2,770
Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability, Total	8		8		$ 908
Derivative, Gain (Loss) on Derivative, Net, Total	$ 289	$ 2,973	$ 900	$ 3,172

Note 9 - Derivatives - Change i

Note 9 - Derivatives - Change in Fair Value of Derivative Liabilities 2 (Details) - USD ($)	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023
Derivative liability balance	$ 367	$ 1,376	$ 12,880	$ 13,833
Gain recognized to revalue derivative instrument at fair value	(359)	(1,009)	(7,308)	(953)
Derivative liability balance	$ 8	$ 367	$ 5,572	$ 12,880

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity, Stock Options and Warrants (Details Textual)			2 Months Ended	3 Months Ended		6 Months Ended
	Apr. 19, 2023 shares	Mar. 16, 2023 $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	May 03, 2024 USD ($) $ / shares	Dec. 31, 2023 $ / shares shares
Preferred Stock, Shares Authorized			20,000,000	20,000,000		20,000,000			20,000,000
Common Stock, Shares Authorized	200,000,000		200,000,000	200,000,000		200,000,000			200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.01	$ 0.01		$ 0.01		$ 0.01	$ 0.01
Proceeds from Issuance of Common Stock | $						$ 3,695,848	$ 0
Share-Based Payment Arrangement, Expense | $				$ 307	$ 5,872	1,040	$ 15,159
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $			$ 182	$ 182		$ 182
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Month)						10 months
Sales Agreement [Member]
Sale of Stock, Maximum Amount | $								$ 3,696,000
Sale of Stock, Commissions, Percent								3%
Stock Issued During Period, Shares, New Issues (in shares)			1,607,100
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 2.3	$ 2.3		$ 2.3
Proceeds from Issuance of Common Stock | $			$ 3,696,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20
Reverse Stock Split [Member] | Minimum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	2
Reverse Stock Split [Member] | Maximum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	25
Series F Preferred Stock [Member]
Preferred Stock, Shares Authorized		80,000
Preferred Stock, Par or Stated Value Per Share | $ / shares		$ 0.01
Preferred Stock Dividends, Shares Per Share		0.001
Preferred Stock, Shares Issued		79,404
Preferred Stock, Voting Rights Per Share		1,000,000
Preferred Stock, Shares Outstanding (in shares)	0
Series F Preferred Stock [Member] | O 2023 Q1 Dividends [Member]
Dividends Payable, Date of Record		Mar. 27, 2023

Note 10 - Stockholders' Equit_4

Note 10 - Stockholders' Equity, Stock Options and Warrants - Stock Offerings (Details)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Expected dividend yield	0%	0%
Expected stock price volatility	0%
Risk-free interest rate	0%
Expected life (years) (Year)		10 years
Minimum [Member]
Expected stock price volatility		90.80%
Risk-free interest rate		3.38%
Maximum [Member]
Expected stock price volatility		91.60%
Risk-free interest rate		3.72%

Note 10 - Stockholders' Equit_5

Note 10 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details)	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Number of Shares Outstanding (in shares)	1,806,589
Average Exercise Price Outstanding (in dollars per share) | $ / shares	$ 21.52
Number of Shares Issued (in shares)	0
Average Exercise Price Issued (in dollars per share) | $ / shares	$ 0
Number of Shares Forfeited (in shares)	0
Expired, warrants (in shares)	(77,285)
Average Exercise Price Expired (in dollars per share) | $ / shares	$ 33.86
Number of Shares Outstanding (in shares)	1,729,304
Average Exercise Price Outstanding (in dollars per share) | $ / shares	$ 20.97
Share-Based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	47,664
Average Exercise Price Outstanding (in dollars per share) | $ / shares	$ 82.23
Number of Shares Issued (in shares)	0
Average Exercise Price Issued (in dollars per share) | $ / shares	$ 0
Number of Shares Forfeited (in shares)	(233)
Average Exercise Price Forfeited (in dollars per share) | $ / shares	$ 4.67
Expired, options (in shares)	(1,019)
Expired, options, average exercise price (in dollars per share) | $ / shares	$ 105.99
Number of Shares Outstanding (in shares)	46,412
Average Exercise Price Outstanding (in dollars per share) | $ / shares	$ 82.09

Note 11 - Loss Per Share - Shar

Note 11 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net loss attributable to common stockholders: basic and diluted calculation		$ (3,181,261)	$ (3,923,368)	$ (7,400,104)	$ (7,345,170)
Weighted average shares used in computation – basic and diluted (in shares)		4,664,771	3,996,512	4,363,812	3,982,384
Effect of diluted stock options, warrants, and preferred stock (1) (in shares)	[1]	0	0	0	0
Weighted average common shares outstanding - diluted (in shares)		4,664,771	3,996,512	4,363,812	3,982,384
Net (loss) per common share – basic and diluted (in dollars per share)		$ (0.68)	$ (0.98)	$ (1.7)	$ (1.84)
[1]The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive:

Note 11 - Loss Per Share - Anti

Note 11 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares) (in shares)	46,412	48,037
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities (in shares) (in shares)	0	2,500
Warrant [Member]
Antidilutive Securities (in shares) (in shares)	1,729,304	1,812,379
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares) (in shares)	16	16

Note 12 - Segments (Details Tex

Note 12 - Segments (Details Textual)	6 Months Ended
	Jun. 30, 2024
Number of Operating Segments	3
Number of Tumor Samples	150,000

Note 12 - Segments - Segments (

Note 12 - Segments - Segments (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Revenue	$ 278,722		$ 490,110	$ 698,368	$ 730,005
Assets	10,587,126			10,587,126		$ 14,417,249
Depreciation and Amortization	(164,165)		(180,135)	(326,730)	(417,989)
Net loss	(3,181,261)	$ (4,218,843)	(3,923,368)	(7,400,104)	(7,345,170)
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Revenue	0		0	0	0
Assets	5,782,586			5,782,586		8,782,034
Depreciation and Amortization	(1,819)		(2,023)	(3,670)	(3,677)
Net loss	(1,445,691)		(1,461,651)	(3,813,731)	(2,956,255)
Pittsburgh [Member] | Operating Segments [Member]
Revenue	67,255		13,844	72,113	24,471
Assets	2,968,289			2,968,289		3,263,270
Depreciation and Amortization	(31,408)		(31,945)	(63,505)	(143,767)
Net loss	(1,010,978)		(1,594,587)	(2,207,043)	(2,753,692)
Birmingham [Member] | Operating Segments [Member]
Revenue	20,813		84,880	31,822	98,529
Assets	696,017			696,017		981,914
Depreciation and Amortization	(123,714)		(136,194)	(244,508)	(253,794)
Net loss	(459,012)		(585,443)	(924,174)	(1,068,139)
Eagan [Member] | Operating Segments [Member]
Revenue	190,654		391,386	594,433	607,005
Assets	1,140,234			1,140,234		$ 1,390,031
Depreciation and Amortization	(7,224)		(9,973)	(15,047)	(16,751)
Net loss	$ (265,580)		$ (281,687)	$ (455,156)	$ (567,084)

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)	Jul. 25, 2024	Jun. 30, 2024	Dec. 31, 2023
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 20.97	$ 21.52
The February 2021, June 2021, and May 2022 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 14
Subsequent Event [Member] | The February 2021, June 2021, and May 2022 Warrants [Member]
Class of Warrant or Right Exercised During Period (in shares)	958,117
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)	$ 1.32
Proceeds from Warrant Exercises	$ 1,260,000
Subsequent Event [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	958,117
Warrants and Rights Outstanding, Term (Year)	5 years
Subsequent Event [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	958,117
Warrants and Rights Outstanding, Term (Year)	18 months
Subsequent Event [Member] | Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.07
Subsequent Event [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.65
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	67,068
Warrants and Rights Outstanding, Term (Year)	5 years
Warrants or Rights, Commissions, Percent	7%
Warrants or Rights, Management Fee, Percent	1%
Warrants or Rights, Issuance Expenses	$ 35,000
Warrants or Rights, Clearing Fees	$ 15,950
Warrants or Rights, Placement Agent Fee, Percent	7%